Elevar Therapeutics
Korea - SeoulBiotechnology
Focus: Elevar Therapeutics is a newly founded (2024) Seoul-based oncology-focused biotech company developing multi-asset pipeline targeting solid tumors and rare cancers. The company operates as a pre-revenue stage biotech with early-to-mid clinical programs.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Open Jobs
2
Should You Work at Elevar Therapeutics?
AI assessmentA speculative career move suitable only for biotech specialists seeking maximum upside in an unproven Seoul-based oncology startup with meaningful clinical assets but minimal operational scale.
Why Work Here
- Early-stage opportunity: Founded in 2024, join a company building from the ground up with defined oncology focus and emerging clinical pipeline across multiple modalities
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Slowing
Jobs decreasing
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Apatinib
Advanced MalignanciesClinical Trials (1)
NCT03407976Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies
Phase 1Help build intelligence for Elevar Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.